Abbott Laboratories (ETR:ABL)
117.00
-0.08 (-0.07%)
Jun 12, 2025, 11:53 AM CET
Abbott Laboratories Revenue
Abbott Laboratories had revenue of $10.36B USD in the quarter ending March 31, 2025, with 3.95% growth. This brings the company's revenue in the last twelve months to $42.34B, up 5.00% year-over-year. In the year 2024, Abbott Laboratories had annual revenue of $41.95B with 4.59% growth.
Revenue (ttm)
$42.34B
Revenue Growth
+5.00%
P/S Ratio
5.23
Revenue / Employee
$371.44K
Employees
114,000
Market Cap
204.96B EUR
Revenue Chart
* This company reports financials in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 41.95B | 1.84B | 4.59% |
Dec 31, 2023 | 40.11B | -3.54B | -8.12% |
Dec 31, 2022 | 43.65B | 578.00M | 1.34% |
Dec 31, 2021 | 43.08B | 8.47B | 24.47% |
Dec 31, 2020 | 34.61B | 2.70B | 8.48% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Siemens Healthineers AG | 23.14B |
Merck KGaA | 21.32B |
Bayer Aktiengesellschaft | 46.58B |
Fresenius SE & Co. KGaA | 22.13B |
Fresenius Medical Care AG | 19.49B |
Sartorius Aktiengesellschaft | 3.44B |
Carl Zeiss Meditec AG | 2.17B |
Fielmann Group AG | 2.33B |
Abbott Laboratories News
- 1 day ago - The Highest-Quality Dividend Contenders By Quality Scores - Seeking Alpha
- 2 days ago - Peering Into Abbott Laboratories's Recent Short Interest - Benzinga
- 5 days ago - Healthcare companies are hiring. Is it time to look for growth stocks in this beaten-down sector? - Market Watch
- 7 days ago - Sainte Nutritional Files For Hong Kong IPO - Benzinga
- 8 days ago - Faulty prostate cancer tests leave 406 Hong Kong patients with nervy wait - South China Morning Post
- 15 days ago - Best Dividend Aristocrats For June 2025 - Seeking Alpha
- 15 days ago - Abbott Receives FDA Approval for Tendyne™, First-of-Its-Kind Device to Replace the Mitral Valve Without Open-Heart Surgery - PRNewsWire
- 16 days ago - Abbott Laboratories: Why Wall Street's Skepticism Misses The Real Story - Seeking Alpha